Acadia Healthcare Shares Surge After Einhorn's Endorsement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy ACHC?
Source: seekingalpha
Acadia Healthcare (ACHC) shares surged approximately 12% on Wednesday after hedge fund manager David Einhorn endorsed the company, indicating growing market confidence in its future prospects.
The stock's rise follows a significant endorsement from David Einhorn, which has led to increased investor interest, as evidenced by nearly 6 million shares traded, far exceeding the 65-day average of 3.4 million shares. This surge also marks the second-largest intraday gain for 2026, reflecting a potential rebound in market expectations for Acadia.
This rally comes after a challenging year for Acadia, which saw a decline of over 64%. However, with new leadership under CEO Debra Osteen since January 2023, the company has gained approximately 9% year-to-date, suggesting a positive shift in its trajectory.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHC
Wall Street analysts forecast ACHC stock price to fall
11 Analyst Rating
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 25.140
Low
13.00
Averages
18.10
High
25.00
Current: 25.140
Low
13.00
Averages
18.10
High
25.00
About ACHC
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its specialty treatment facilities include residential recovery facilities and eating disorder facilities. Its comprehensive treatment centers specialize in providing medication-assisted treatment in an outpatient setting. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. It operates a network of 262 behavioral healthcare facilities with over 11,850 beds in 39 states and Puerto Rico.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
Canyon Capital Fully Exits Acadia Healthcare Position
- Shareholding Change: Canyon Capital sold 521,774 shares of Acadia Healthcare in Q4, resulting in a decrease of approximately $12.92 million in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Although Acadia Healthcare reported a 6.1% revenue increase to $821.5 million in Q4, the adjusted EBITDA fell to $608.9 million due to a $996.2 million goodwill impairment, highlighting the financial pressures the company faces.
- Market Environment: Acadia Healthcare's stock has declined about 20% over the past year, with a staggering drop of up to 60% in recent months, reflecting the company's vulnerability amid broader financial pressures, warranting caution from investors.
- Investment Strategy Shift: Canyon Capital's exit suggests a preference for asset-backed recovery plays over healthcare turnaround risks, necessitating close monitoring of Acadia's occupancy trends and liability reserve stability moving forward.
See More
Acadia Healthcare Receives Overweight Rating
- Rating Analysis: Acadia Healthcare (ACHC) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target: The average price target set by analysts is $22, suggesting there is room for stock price appreciation, which could yield substantial returns for investors if achieved.
- Market Confidence: The overweight rating reflects market confidence in Acadia Healthcare's continued growth potential within the healthcare sector, potentially driving its stock price higher.
- Investment Appeal: With analysts' positive evaluations of Acadia Healthcare, it is expected to attract more institutional investors, further enhancing its market performance.
See More
Acadia Healthcare Q4 2025 Earnings Call Insights
- Leadership Transition: CEO Debra Osteen emphasized a renewed focus on stability and execution, planning to enhance company performance by reinforcing operational discipline and supporting field teams, aiming to lay a foundation for future success.
- Financial Performance Review: Q4 2025 revenue reached $821.5 million, a 6.1% year-over-year increase, with adjusted EBITDA at $99.8 million, reflecting a 4.4% growth in same-facility revenue driven by a 1.3% increase in revenue per patient day and a 3.1% rise in patient days.
- Future Outlook: The company expects 2026 revenue between $3.37 billion and $3.45 billion, with adjusted EBITDA projected at $575 million to $610 million, reflecting expectations for same-facility growth and anticipated start-up losses from new facilities.
- Capital Expenditure Management: Total capital expenditures for 2025 amounted to $572 million, below guidance, with management stressing that each project must demonstrate clear market fundamentals and patient needs to ensure effective capital utilization.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for Generalized Anxiety Disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a robust annual growth rate of approximately 9%, driven by increasing awareness of mental health and demand for innovative solutions.
- Diverse Treatment Options: In addition to traditional anti-anxiety and antidepressant medications, the rise of cognitive-behavioral therapy and digital mental health tools has enhanced accessibility and effectiveness, allowing patients to manage symptoms in more flexible ways.
- Helus Pharma Drug Development: Helus Pharma announced positive topline results from its Phase 2 signal detection study for HLP004, indicating significant potential for this treatment to benefit adults with moderate-to-severe GAD who have not responded to existing therapies, thus offering new hope for underserved patients.
- Investment Outlook: As mental health care becomes increasingly integrated into mainstream healthcare systems, the broader anxiety treatment market is expected to exceed $12 billion in the next decade, with ongoing investments from companies and investors likely to drive long-term growth in this sector.
See More
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
- Market Growth Potential: The global market for generalized anxiety disorder (GAD) treatments is projected to grow from $1.8 billion in 2023 to $4.26 billion by 2033, reflecting a 9% annual growth rate driven by increasing awareness of mental health and demand for innovative solutions.
- Therapeutic Innovation: Helus Pharma's HLP004 demonstrated significant efficacy in a Phase 2 clinical trial for moderate-to-severe GAD patients, achieving an average reduction of 10.4 points in the Hamilton Anxiety Rating Scale (p<0.0001) within six weeks, offering new hope for patients who have not responded to existing treatments.
- Positive Patient Response: At six months, 67% of participants showed treatment response and 39% achieved remission, indicating that HLP004 provides durable effects and could potentially transform the treatment landscape for GAD.
- Optimistic Industry Outlook: The rise of digital mental health tools and telehealth has significantly improved treatment accessibility, and investments by Helus Pharma and other companies in mental health solutions are expected to drive continued market growth to meet the increasing patient demand.
See More
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
Canyon Capital Fully Exits Acadia Healthcare Position
- Shareholding Change: Canyon Capital sold 521,774 shares of Acadia Healthcare in Q4, resulting in a decrease of approximately $12.92 million in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Although Acadia Healthcare reported a 6.1% revenue increase to $821.5 million in Q4, the adjusted EBITDA fell to $608.9 million due to a $996.2 million goodwill impairment, highlighting the financial pressures the company faces.
- Market Environment: Acadia Healthcare's stock has declined about 20% over the past year, with a staggering drop of up to 60% in recent months, reflecting the company's vulnerability amid broader financial pressures, warranting caution from investors.
- Investment Strategy Shift: Canyon Capital's exit suggests a preference for asset-backed recovery plays over healthcare turnaround risks, necessitating close monitoring of Acadia's occupancy trends and liability reserve stability moving forward.
See More
Acadia Healthcare Receives Overweight Rating
- Rating Analysis: Acadia Healthcare (ACHC) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target: The average price target set by analysts is $22, suggesting there is room for stock price appreciation, which could yield substantial returns for investors if achieved.
- Market Confidence: The overweight rating reflects market confidence in Acadia Healthcare's continued growth potential within the healthcare sector, potentially driving its stock price higher.
- Investment Appeal: With analysts' positive evaluations of Acadia Healthcare, it is expected to attract more institutional investors, further enhancing its market performance.
See More
Acadia Healthcare Q4 2025 Earnings Call Insights
- Leadership Transition: CEO Debra Osteen emphasized a renewed focus on stability and execution, planning to enhance company performance by reinforcing operational discipline and supporting field teams, aiming to lay a foundation for future success.
- Financial Performance Review: Q4 2025 revenue reached $821.5 million, a 6.1% year-over-year increase, with adjusted EBITDA at $99.8 million, reflecting a 4.4% growth in same-facility revenue driven by a 1.3% increase in revenue per patient day and a 3.1% rise in patient days.
- Future Outlook: The company expects 2026 revenue between $3.37 billion and $3.45 billion, with adjusted EBITDA projected at $575 million to $610 million, reflecting expectations for same-facility growth and anticipated start-up losses from new facilities.
- Capital Expenditure Management: Total capital expenditures for 2025 amounted to $572 million, below guidance, with management stressing that each project must demonstrate clear market fundamentals and patient needs to ensure effective capital utilization.
See More
